Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

First-line pola-R-CHP in diffuse large B cell lymphoma: A single-center real-world data analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJie Sun

Discussion

Loading...

Member takes

Overview

Real-world data reveals lower complete response rates with first-line Pola-R-CHP in high-risk DLBCL, suggesting socioeconomic factors impact outcomes.

Key Points

  • Evaluate the efficacy of first-line Pola-R-CHP therapy in high-risk diffuse large B-cell lymphoma patients.
  • Retrospective analysis of newly diagnosed CD20-positive DLBCL patients
  • Analyzed outcomes such as complete response, overall response rate, progression-free survival, and overall survival
  • Conducted next-generation sequencing in a subset of patients
  • Post-treatment complete response rate was 47.5%
  • Overall response rate was 82.5%
  • 12-month progression-free survival was 92.3%, overall survival was 94.3%

Cite This Study

Jie Sun (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e299https://doi.org/10.1182/blood-2025-7212
View Full Paper
Ask AI
Bookmark
Share